Therapeutic Response

dMMR status confers therapeutic sensitivity to Dostarlimab in patients with Any solid tumor.

Statements

Source and description
Jemperli (dostarlimab) [package insert]. FDA. The U.S. Food and Drug Administration granted accelerated approval to dostarlimab for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-Approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.